Grifols, S.A.
https://www.grifols.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Grifols, S.A.
CTAD 2023: Grifols/Araclon Ponder Next Steps For ABvac40 After Phase II Readout
The Phase II trial was not powered to show statistical significance on cognitive efficacy, but early Alzheimer’s patients treated with Araclon/Grifols’ anti-Aβ40 vaccine had slower decline by some measures.
Schizophrenia, Depression And Neuropathy: What’s Coming In 2024
The following four neurological products are likely to reach market next year. Carving out sales will be an entirely different problem.
Finance Watch: Many Mega-Rounds, Some Smaller VC Deals, But Few In The Middle
Private Company Edition: June’s eight $100m-plus venture capital rounds already outpace the seven each raised in March, April and May, including €255m ($274.2m) for ITM and $200m for Upstream, but while there were five $25m or less VC financings during the past week, mid-sized deals were lacking.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 9: The Natural Environment
Improving human health is the raison d’etre of the biopharma sector. But what can the industry do to safeguard and improve the health of Planet Earth? Executives shared their thoughts with Scrip.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Diagnostic Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Alpha Therapeutic Corporation
- Biotest AG
- Goetech LLC
- GigaGen, Inc.
- Grifols Therapeutics, Inc.
- MedKeeper
- Talecris Biotherapeutics Inc.
- Haema AG.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice